CollPlant Biotechnologies has announced encouraging non-clinical results for its photocurable regenerative dermal and soft tissue filler. The company is preparing for clinical trials, a key step toward transforming the future of aesthetic and regenerative treatments.
A new era in filler technology
CollPlant Biotechnologies’ innovation stands out for combining precision contouring, strong structural support, and natural tissue regeneration in a single treatment. Conventional fillers mainly use hyaluronic acid (HA) for volume restoration. This new formulation combines HA with CollPlant’s modified recombinant human collagen (rhCollagen).
The result is a viscoelastic gel that can be injected with fine precision. Once sculpted to the desired shape, it is exposed to light using CollPlant’s proprietary illumination device. The process turns the gel into a semi-solid implant that holds shape, resists gravity, and naturally blends with tissue.
Harnessing rhCollagen for regeneration
At the heart of this breakthrough lies rhCollagen, CollPlant’s non-animal, bioengineered collagen platform. Known for its purity and structural similarity to native human collagen, it provides an ideal scaffold for cell growth and tissue regeneration. This enables a dual benefit of immediate aesthetic enhancement and long-term biological integration.
Yehiel Tal, CEO of CollPlant, remarked, “By harnessing the unique properties of our rhCollagen technology, we aim to redefine the standard of care in aesthetic medicine, offering a solution that not only provides instant results but also promotes natural regeneration for sustained outcomes.”
Building a strong foundation for clinical success
The completed non-clinical programme included safety and performance studies, with a one-year trial confirming long-term durability and global biocompatibility. These findings provide a solid foundation as the company scales up manufacturing and refines its processes in preparation for clinical trials.
Shaping the future of regenerative aesthetics
As aesthetic medicine embraces regenerative, durable, and biocompatible solutions, CollPlant Biotechnologies’ photocurable filler may mark a key industry moment. By bridging advanced biomaterials with practical clinical application, the company is moving closer to a future where beauty and biology work seamlessly together.